Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61^st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.

Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494. In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress. We look forward to participating in this important event.”

Oxylanthanum Carbonate (OLC)

Title:	Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats
Lead Author:	Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:10 p.m. – 12:15 p.m. CEST
Title:	Oxylanthanum Carbonate for Hyperphosphatemia in End Stage Kidney Disease (ESKD): Tolerability Trial in Progress
Lead Author:	Pablo E. Pergola, M.D., Ph.D., Renal Associates, P.A.
Type:	ePoster
Date/Time:	Available throughout the conference

UNI-494

Title:	Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function
Lead Author:	Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:00 p.m. – 12:05 p.m. CEST
Title:	UNI-494 Phase I Tolerability and Pharmacokinetics: Trial in Progress
Lead Author:	Guru Reddy, Ph.D., Vice President of Preclinical R&D, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:45 p.m. – 12:50 p.m. CEST

About Oxylanthanum Carbonate (OLC)